PMC:7253482 / 191-369
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"41","span":{"begin":7,"end":15},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D015047"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":95,"end":102},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}
LitCovid-sample-PD-IDO
{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T1","span":{"begin":16,"end":25},"obj":"http://purl.obolibrary.org/obo/IDO_0000528"},{"id":"T2","span":{"begin":147,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006959"},{"id":"T3","span":{"begin":155,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}
LitCovid-sample-Enju
{"project":"LitCovid-sample-Enju","denotations":[{"id":"T27","span":{"begin":1,"end":2},"obj":"-RRB-"},{"id":"T28","span":{"begin":3,"end":6},"obj":"VBP"},{"id":"T29","span":{"begin":7,"end":15},"obj":"JJ"},{"id":"T30","span":{"begin":16,"end":25},"obj":"NNS"},{"id":"T31","span":{"begin":26,"end":30},"obj":"IN"},{"id":"T32","span":{"begin":31,"end":35},"obj":"JJ"},{"id":"T33","span":{"begin":36,"end":44},"obj":"NN"},{"id":"T34","span":{"begin":45,"end":50},"obj":"NNS"},{"id":"T35","span":{"begin":51,"end":54},"obj":"CC"},{"id":"T36","span":{"begin":55,"end":63},"obj":"JJ"},{"id":"T37","span":{"begin":64,"end":73},"obj":"NN"},{"id":"T38","span":{"begin":75,"end":82},"obj":"NN"},{"id":"T39","span":{"begin":83,"end":94},"obj":"NN"},{"id":"T40","span":{"begin":95,"end":102},"obj":"VBZ"},{"id":"T41","span":{"begin":103,"end":105},"obj":"IN"},{"id":"T42","span":{"begin":106,"end":109},"obj":"DT"},{"id":"T43","span":{"begin":110,"end":119},"obj":"JJ"},{"id":"T44","span":{"begin":120,"end":126},"obj":"NN"},{"id":"T45","span":{"begin":127,"end":129},"obj":"IN"},{"id":"T46","span":{"begin":130,"end":133},"obj":"DT"},{"id":"T47","span":{"begin":134,"end":146},"obj":"VBG"},{"id":"T48","span":{"begin":147,"end":154},"obj":"JJ"},{"id":"T49","span":{"begin":155,"end":161},"obj":"JJ"},{"id":"T50","span":{"begin":162,"end":170},"obj":"NN"},{"id":"T51","span":{"begin":170,"end":171},"obj":"-COMMA-"},{"id":"T52","span":{"begin":172,"end":175},"obj":"DT"}],"relations":[{"id":"R26","pred":"arg2Of","subj":"T30","obj":"T28"},{"id":"R27","pred":"arg1Of","subj":"T30","obj":"T29"},{"id":"R28","pred":"arg1Of","subj":"T30","obj":"T31"},{"id":"R29","pred":"arg2Of","subj":"T35","obj":"T31"},{"id":"R30","pred":"arg1Of","subj":"T34","obj":"T32"},{"id":"R31","pred":"arg1Of","subj":"T34","obj":"T33"},{"id":"R32","pred":"arg1Of","subj":"T34","obj":"T35"},{"id":"R33","pred":"arg2Of","subj":"T37","obj":"T35"},{"id":"R34","pred":"arg1Of","subj":"T37","obj":"T36"},{"id":"R35","pred":"arg1Of","subj":"T39","obj":"T38"},{"id":"R36","pred":"arg1Of","subj":"T39","obj":"T40"},{"id":"R37","pred":"arg1Of","subj":"T40","obj":"T41"},{"id":"R38","pred":"arg2Of","subj":"T44","obj":"T41"},{"id":"R39","pred":"arg1Of","subj":"T44","obj":"T42"},{"id":"R40","pred":"arg1Of","subj":"T44","obj":"T43"},{"id":"R41","pred":"arg1Of","subj":"T44","obj":"T45"},{"id":"R42","pred":"arg2Of","subj":"T50","obj":"T45"},{"id":"R43","pred":"arg1Of","subj":"T50","obj":"T46"},{"id":"R44","pred":"arg1Of","subj":"T50","obj":"T47"},{"id":"R45","pred":"arg1Of","subj":"T50","obj":"T48"},{"id":"R46","pred":"arg1Of","subj":"T50","obj":"T49"},{"id":"R47","pred":"arg1Of","subj":"T50","obj":"T51"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}
LitCovid-sample-Pubtator
{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"41","span":{"begin":7,"end":15},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"pubann:denotes","subj":"41","obj":"MESH:D015047"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}
LitCovid-sample-PD-GO-BP-0
{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T2","span":{"begin":147,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006959"},{"id":"T3","span":{"begin":155,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}
LitCovid-sample-GO-BP
{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T2","span":{"begin":147,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006959"},{"id":"T3","span":{"begin":155,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":147,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006959"},{"id":"T3","span":{"begin":155,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"s) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the sp"}